摘要
目的探讨ArcCHECK-3DVH剂量验证系统在宫颈癌容积旋转调强放射治疗(VMAT)三维剂量验证中的应用。方法选取2021年1—12月于医院行VMAT的20例宫颈癌术后患者,利用ArcCHECK-3DVH剂量验证系统进行计划验证,比较ArcCHECK-3DVH剂量验证系统重建剂量与治疗计划系统(TPS)计算剂量的三维γ通过率,以及计划靶区(PTV)的98%体积受量(D_(98%))、2%体积受量(D_(2%))、平均剂量(D_(mean))与危及器官剂量参数。结果20例宫颈癌患者的PTV和危及器官的整体3 mm/3%γ通过率为(93.58±2.9)%。PTV和危及器官的ArcCHECK-3DVH剂量验证系统重建剂量均大于TPS计算剂量。PTV的D_(98%)、D_(2%)和D_(mean)的ArcCHECK-3DVH剂量验证系统重建值与TPS计算值的差异分别为(0.95±0.80)%、(2.93±1.38)%和[2.0(1.42,2.17)]%,均小于3%,且差异有统计学意义(P<0.05)。小肠、直肠、膀胱和左右股骨头的3 mm/3%γ通过率均大于95%,骨髓的γ通过率为(94.79±2.70)%,均满足临床要求。左右侧股骨头的V_(40)和V_(30)的ArcCHECK-3DVH剂量验证系统重建值与TPS计算值差异较大,分别为V_(40)[34.05(18.86,62.89)%,29.88(20.61,52.11)%]和V_(30)[(14.51±8.44)%,11.01(8.02,13.90)%],且差异有统计学意义(P<0.05);除膀胱的V_(20)及骨髓的V_(20)、V_(10)外,危及器官其他剂量参数的ArcCHECK-3DVH剂量验证系统重建值与TPS计算值的差异均有统计学意义(P<0.05)。结论ArcCHECK-3DVH剂量验证系统应用于宫颈癌VMAT三维剂量验证中,可以提供PTV和危及器官的测量重建剂量和TPS计算剂量的具体差异,有助于提高计划验证的准确性。
Objective The application of ArcCHECK-3DVH dose verification system in three-dimensional dose verification of volumetric modulated arc therapy(VMAT)for cervical cancer was investigated.Methods With the selection of 20 patients with cervical cancer received VMAT from January to December 2021 in the hospital after surgery,the ArcCHECK-3DVH dose verification system was used for plan verification.The 3D γ-pass rates,98% volume dose(D_(98%)),2% volume dose(D_(2%)),average dose(D_(mean))and dose parameters of dangerous organs in the planned target area(PTV)of reconstructed dose in ArcCHECK-3DVH dose verification system were compared with that of calculated dose in treatment planning system(TPS).Results The overall 3 mm/3% γ pass rate of PTV and endangered organs in 20 patients with cervical cancer was(93.58±2.9)%.The reconstructed doses of ArcCHECK-3DVH dose verification system for PTV and organs at risk were greater than the calculated doses of TPS.The difference between the reconstructed values of D_(98%),D_(2%) and D_(mean) for PTV in ArcCHECK-3DVH dose verification system and the calculated values of TPS was(0.95±0.80)%,(2.93±1.38)% and[2.0(1.42,2.17)]%,respectively,less than 3%,and the difference was statistically significant(P<0.05).The 3mm/3% γ pass rate of small intestine,rectum,bladder,left and right femoral head was greater than 95%,and 3mm/3% γ pass rate of bone marrow was(94.79±2.70)%,which met the clinical requirements.The reconstruction dose of the ArcCHECK-3DVH dose verification system for V_(40) and V_(30) in the left and right femoral heads was significantly different from the calculated dose of TPS,which were V_(40)[34.05(18.86,62.89)%,29.88(20.61,52.11)%]and V_(30)[(14.51±8.44)%,11.01(8.02,13.90)%],respectively,and the difference was statistically significant(P<0.05);Except for V_(20) of bladder,V_(20) and V_(10) of bone marrow,the reconstructed value of ArcCHECK-3DVH dose verification system for other dose parameters in endangering organs was significantly different from the calculated valu
作者
陈伟思
史亚滨
陈洪涛
郑芳
张定
付鑫
钟鹤立
Chen Weisi;Shi Yabin;Chen Hongtao;Zheng Fang;Zhang Ding;Fu Xin;Zhong Heli(Department of Cance radiotherapy,Shenzhen People's Hospital(The Second Clinical Medical Colloge of Jinan University/The First Affiliated Hospital of Southern University of Science and Technology),Shenzhen Guangdong 518010,China)
出处
《医疗装备》
2022年第21期1-5,共5页
Medical Equipment
基金
海南省卫生计生行业科研项目(19A200096)。
